Non-Alcoholic Steatohepatitis (NASH) Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, Canada, China, UK - Size and Forecast 2024-2028

Non-Alcoholic Steatohepatitis (NASH) Market Size 2024-2028

The non-alcoholic steatohepatitis (nash) market size is forecast to increase by USD 31.46 billion at a CAGR of 58.37% between 2023 and 2028.

• The market represents a significant growth opportunity, driven by the rising prevalence of obesity and metabolic syndrome, two major risk factors for this liver condition. According to the American Association for the Study of Liver Diseases, approximately 2-5% of the US population and up to 30% of obese individuals are estimated to have NASH. This trend is mirrored globally, with the International Journal of Epidemiology projecting a 66% increase in NASH cases by 2030. Another key driver for market growth is the increasing patient engagement and education surrounding liver health. Patients are becoming more aware of the importance of managing their condition, leading to a greater demand for effective treatment options.
• However, the lack of approved therapies for NASH presents a significant challenge for the market. Currently, there are no FDA-approved medications specifically for NASH, and existing treatments primarily focus on managing symptoms or addressing complications. Companies seeking to capitalize on this market opportunity must invest in research and development to bring innovative solutions to market. These could include novel therapeutic approaches, such as antifibrotic and antioxidant agents, or lifestyle modifications, such as diet and exercise interventions. By addressing the unmet need for effective NASH treatments, companies can differentiate themselves and gain a competitive edge in this growing market.

What will be the Size of the Non-Alcoholic Steatohepatitis (NASH) Market during the forecast period?

Request Free Sample

• The market in the US is experiencing significant activity due to the growing prevalence of metabolic syndrome, obesity, and insulin resistance. NASH is a chronic liver condition characterized by inflammation, steatosis, and fibrosis in the absence of significant alcohol consumption. Symptoms include pain, jaundice, itchy skin, fluid accumulation, and enlarged liver. The market is driven by the increasing number of diagnosed cases, which are estimated to reach millions in the coming years. The pipeline for NASH treatments is , with various antidiabetes agents, weight management medications, and Bone Morphogenetic Protein (BMP) therapies under development. Diagnosis techniques, such as physical examination, blood tests, ultrasound, and liver biopsy, are essential in identifying and managing the disease.
• Healthcare expenditure on NASH treatment is expected to increase due to the high cost of medication and potential need for liver transplant in severe cases. Overall, the NASH market is a growing concern for healthcare providers and payers, with a significant impact on patient quality of life and healthcare costs.

How is this Non-Alcoholic Steatohepatitis (NASH) Industry segmented?

The non-alcoholic steatohepatitis (nash) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Distribution Channel
  • Offline
  • Online
• Application
  • Diagnosis
  • Treatment
• Geography
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

By Distribution Channel Insights

The offline segment is estimated to witness significant growth during the forecast period.

Non-alcoholic steatohepatitis (NASH) is a chronic liver condition characterized by inflammation and liver damage caused by accumulation of fat in the liver without alcohol consumption. Symptoms include fatigue, abdominal discomfort, weakness, jaundice, pain, itchy skin, and spider veins. NASH can lead to cirrhosis, increased lifespan, and premature death. Genetics and metabolic syndrome, including insulin resistance, obesity, and high triglycerides, contribute to its development. Diagnostic techniques include physical examination, blood tests, ultrasound, transient elastography, and liver biopsy. Several pharmaceutical companies, such as Genfit, Intercept Pharmaceuticals, Inventiva, AbbVie, Boehringer Ingelheim, Akero Therapeutics, Phenex Pharmaceuticals, and others, are developing medications for NASH treatment.

Lifestyle modifications, including weight loss, weight management, and sedentary lifestyle reduction, are essential for managing NASH. Symptoms alleviation and improved liver health can be achieved through panPPAR agonists, antidiabetes agents, and other therapeutic approaches. Regular monitoring and follow-up appointments are necessary for patients with NASH to ensure proper management and prevent complications such as fluid accumulation, cardiovascular diseases, and liver damage. Offline distribution of diagnostic tests and educational materials plays a crucial role in raising awareness and early detection of NASH.

Get a glance at the market report of share of various segments Request Free Sample

The Offline segment was valued at USD 846.80 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 51% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

Non-alcoholic steatohepatitis (NASH), a condition marked by inflammation and liver damage due to fat accumulation, is a growing health concern in North America. Obesity, type 2 diabetes, and sedentary lifestyles are major risk factors fueling its prevalence. The NASH market in North America is expected to expand due to increased awareness, advanced diagnostic techniques, and novel treatment approaches. Symptoms of NASH include fatigue, abdominal discomfort, weakness, and jaundice. Diagnosis involves physical examination, blood tests, ultrasound, and liver biopsy. The disease can lead to complications such as cirrhosis, liver failure, and premature death. NASH is linked to metabolic syndrome, insulin resistance, and high triglycerides.

Genetics and lifestyle factors also play a role. Pharmaceutical companies like Genfit, Intercept Pharmaceuticals, Inventiva, AbbVie, Boehringer Ingelheim, Phenex Pharmaceuticals, and Akero Therapeutics are developing targeted therapies for NASH. These include cilofexor, lanifibranor, and antidiabetes agents. Some treatments focus on improving overall wellbeing, alleviating symptoms, and promoting weight loss. Others target inflammation, liver function, and liver damage. Lifestyle modifications, such as weight management and increased physical activity, are crucial for managing NASH. However, medication may be necessary for symptom relief and disease progression. The market for NASH treatments is growing as research uncovers new insights into the disease's causes and potential treatments.

Transient elastography and other diagnostic techniques are improving the accuracy of NASH diagnosis. The ultimate goal is to prevent complications, improve quality of life, and potentially increase lifespan.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise in the adoption of Non-Alcoholic Steatohepatitis (NASH) Industry?

• Rising prevalence of obesity and metabolic syndrome is the key driver of the market.

• Non-alcoholic steatohepatitis (NASH) is an emerging health concern linked to obesity and metabolic syndrome. The rising prevalence of these conditions increases the risk of developing NASH, leading to a higher incidence of the disease. Healthcare providers are becoming more vigilant in diagnosing NASH due to the growing awareness of its connection to obesity and metabolic syndrome. This heightened diagnostic activity fuels the demand for NASH-related diagnostic tools and services.
• The increasing number of NASH cases driven by obesity and metabolic syndrome necessitates the development of effective treatments. Pharmaceutical companies are investing in research and development to address this demand and provide solutions for those diagnosed with NASH.

What are the market trends shaping the Non-Alcoholic Steatohepatitis (NASH) Industry?

• Rising patient engagement and education is the upcoming market trend.

• Non-alcoholic steatohepatitis (NASH) is a chronic liver condition that warrants increased attention due to its growing prevalence and potential complications. Patient engagement and education play a crucial role in enhancing awareness of NASH among the populace and high-risk individuals. A deeper of NASH risk factors, symptoms, and consequences encourages earlier diagnosis and intervention. Educated patients are empowered to actively participate in their healthcare decisions, fostering productive dialogues with healthcare providers, asking pertinent questions, and implementing lifestyle modifications that favorably impact NASH management.
• These modifications encompass weight loss, healthy eating, and regular physical activity. Engaged patients are more likely to adhere to these changes, ensuring better disease control.

What challenges does the Non-Alcoholic Steatohepatitis (NASH) Industry face during its growth?

• Lack of approved therapies is a key challenge affecting the industry growth.

• Non-alcoholic steatohepatitis (NASH) is a chronic liver condition with limited pharmacological treatment options, posing challenges in managing the disease effectively and preventing its progression. The absence of approved therapies complicates clinical trial design and conduct, requiring the definition of meaningful endpoints and demonstration of efficacy and safety without established benchmarks. Patients with NASH may miss out on targeted treatments, impacting their quality of life, disease progression, and overall outcomes.
• This lack of approved therapies drives innovation in clinical trial strategies, endpoints, and investigational drug development. Despite these challenges, researchers and pharmaceutical companies remain committed to advancing the field and bringing effective treatments to market for NASH patients.

Exclusive Customer Landscape

The non-alcoholic steatohepatitis (nash) market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the non-alcoholic steatohepatitis (nash) market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, non-alcoholic steatohepatitis (nash) market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

AstraZeneca Plc - The company advances research in non-alcoholic steatohepatitis (NASH) treatment through Phase Iib III clinical trials, specifically PROXYMOADVANCE. This innovative approach aims to address the global health concern of NASH, a chronic liver disease, by exploring novel therapeutic solutions. The company's commitment to scientific advancement and dedication to improving patient outcomes positions it at the forefront of the NASH treatment landscape.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• AstraZeneca Plc
• BioPredictive S.A.S
• Cirius Therapeutics
• Enzo Biochem Inc.
• GENFIT SA
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Intercept Pharmaceuticals Inc.
• Inventiva S.A.
• Madrigal Pharmaceuticals Inc.
• Novo Nordisk AS
• Prometheus Laboratories
• Siemens Healthineers AG
• Zydus Lifesciences Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Nonalcoholic Steatohepatitis (NASH) is a chronic liver condition characterized by inflammation and accumulation of fat in the liver, leading to liver damage and potential progression to cirrhosis. This condition is distinct from simple nonalcoholic fatty liver disease (NAFLD), as NASH involves not only fat accumulation but also inflammation and liver cell damage. The global NASH market is witnessing significant growth due to the increasing prevalence of obesity, metabolic syndrome, and insulin resistance. These conditions are major risk factors for the development of NASH. The disease can lead to a range of symptoms, including abdominal discomfort, weakness, lack of concentration, and jaundice.

In severe cases, NASH can result in premature death due to complications such as cardiovascular diseases, liver failure, and liver cancer. Despite the availability of lifestyle modifications, such as weight loss and physical activity, there is currently no cure for NASH. However, several pharmaceutical companies are developing novel therapeutic approaches to address the underlying causes of the disease. These include drugs targeting inflammation, insulin resistance, and fibrosis. One such class of drugs is panppar agonists, which have shown promise in reducing liver inflammation and improving liver function. Companies like Genfit and Inventiva are leading the development of these drugs, with Genfit's elafibranor and Inventiva's lanifibranor being the most advanced in clinical development.

Other companies, such as AbbVie, Boehringer Ingelheim, and Akero Therapeutics, are also pursuing novel approaches to NASH treatment. The diagnosis of NASH can be challenging, as it often presents with nonspecific symptoms and requires a combination of clinical examination, imaging studies, and liver biopsy. Transient elastography and blood tests are commonly used for diagnosis, while ultrasound and physical examination can help identify potential risk factors such as obesity, sedentary lifestyle, and increased waist circumference. The economic burden of NASH is significant, with healthcare expenditure for the treatment of liver diseases continuing to rise. The global market for NASH treatments is expected to grow at a rate in the coming years, driven by the increasing prevalence of risk factors and the unmet need for effective treatments.

Despite the progress being made in the development of new treatments, there are still significant challenges to overcome. These include the complex etiology of NASH, the lack of effective diagnostic tools, and the potential for drug-induced liver toxicity. Nevertheless, the pipeline for NASH treatments is , and several promising therapies are expected to reach the market in the coming years. In , NASH is a significant health concern, with a growing prevalence and a significant economic burden. The development of effective treatments remains a priority, with several pharmaceutical companies pursuing novel approaches to address the underlying causes of the disease.

While challenges remain, the pipeline for NASH treatments is , and several promising therapies are expected to reach the market in the coming years.

Request Free Sample

What are the Key Data Covered in this Non-Alcoholic Steatohepatitis (NASH) Market Research and Growth Report?

• CAGR of the Non-Alcoholic Steatohepatitis (NASH) industry during the forecast period
• Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the non-alcoholic steatohepatitis (nash) market growth of industry companies

We can help! Our analysts can customize this non-alcoholic steatohepatitis (nash) market research report to meet your requirements.

Get in touch